Gilead Sciences, Inc. GILD announced that the FDA has granted accelerated approval to Hepcludex (bulevirtide-gmod) for adults with chronic hepatitis delta virus (HDV) infection. The approval makes ...
Datopotamab deruxtecan is now a first-line targeted therapy for immunotherapy-ineligible metastatic TNBC, addressing the ~70% ...
Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly ...
Merck (MRK) stock gains as a cancer drug the company develops with Kelun-Biotech bests its Keytruda blockbuster in a ...
The Food and Drug Administration in recent months has approved a small number of drugs quite quickly under a new expedited ...
Krystal Biotech is the furthest along in pursuing this approach and is ironing out details of a registrational trial for its ...
The trial failure reinforces Keytruda’s competitive position in first-line metastatic melanoma, where it already outperformed ...
On March 20, the FDA approved Opdivo for adult and pediatric patients (aged 12 years and older) with previously untreated ...
Adding Inhibrx Biosciences’ OX40 agonist to Keytruda doubled the response rate in a midphase clinical trial, encouraging the biotech to advance a program that reportedly attracted the interest of ...
Just a few weeks after President Donald Trump’s December promise that prescription drug prices would plummet "fast and furious," Patricia Brown checked into a California clinic for an infusion of ...
The KEYTRUDA regimen is the first and only PD-1 inhibitor-based treatment approved in the European Union for these patients Approval supported by data from the Phase 3 KEYNOTE-B96 trial in which the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results